BMS and Hengrui forge $15.2bn alliance for early-stage drugs - Pharmaceutical Technology

BMS and Hengrui will trade the greater Chinese and US rights to certain programmes, while joining forces to progress five innovative assets. The two companies will trade the greater Chinese and US rights to certain programmes under their jurisdiction, while working in tandem to progress these assets. The deal between BMS and Hengrui involves 13 assets spanning the disease areas of oncology, haematology and immunology. Credit: PixelBiss / Shutterstock.com. Bristol Myers Squibb (BMS) and Chinese biopharma company Hengrui Pharma have inked one of the largest licensing and collaboration deals in the industry’s history, centering around several early-stage oncology, immunology and…

Source: Pharmaceutical Technology